Current Management of Desmoid Tumors
Bernd Kasper(Heidelberg University), Lorenzo D’Ambrosio(Ospedale San Luigi Gonzaga), Nadège Corradini(Institut d’Hématologie et d’Oncologie Pédiatrique), Aaron R. Weiss(MaineHealth), Michela Casanova(Fondazione IRCCS Istituto Nazionale dei Tumori), Jyoti Bajpai(Tata Memorial Hospital), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Marco Vitellaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Angelo Paolo Dei Tos(University of Padua), Aimeé M. Crago(Memorial Sloan Kettering Cancer Center), Kenneth Cardona(Emory University), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Rebecca A. Gladdy(Princess Margaret Cancer Centre), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Rick L. Haas(Leiden University Medical Center), Chiara Colombo(The University of Texas MD Anderson Cancer Center), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Joseph P. Erinjeri(Memorial Sloan Kettering Cancer Center), Fariba Navid(Children's Hospital of Los Angeles), Nicolas Penel(Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail), Kjetil Boye(Oslo University Hospital), Palma Dileo(University College Hospital), Winette T.A. van der Graaf(The Netherlands Cancer Institute), Chandrajit P. Raut(Dana-Farber Cancer Institute), Daniel Orbach(Université Paris Sciences et Lettres), Steven Attia(Mayo Clinic in Florida), Sylvie Bonvalot(Dana-Farber Cancer Institute), Bernadette Brennan(Media Working Group), D. Strauß(Royal Marsden Hospital), Eldad Elnekave(Shaare Zedek Medical Center), Olga Husson(Erasmus MC), Giacomo Giulio Baldi(Media Working Group), Monika Sparber‐Sauer(Olgahospital), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Alex J. Lazar(The University of Texas MD Anderson Cancer Center), R. Ratan(The University of Texas MD Anderson Cancer Center), Christina Baumgarten(Media Working Group), Jeffrey M. Farma(Fox Chase Cancer Center), Jean‐Emmanuel Kurtz(Université de Strasbourg), Christina L. Roland(The University of Texas MD Anderson Cancer Center), Ann-Rose W. Schut(Erasmus MC Cancer Institute), Andre Domenico Campanacci(Media Working Group), Tom Wie-Wu Chen(Media Working Group), Andrea Ferrari(University of Milan), Livia Prudente Barbieri(Media Working Group), Benjamin A. Alman(Duke University), Elizabeth H. Baldini(Dana-Farber Cancer Institute), Charlotte Benson(Royal Marsden NHS Foundation Trust)
Cited by 95
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k